GenOdyssee Announces Positive Results of Proprietary Interferon-alpha Variants for the Treatment of Hepatitis C and Cancer; In Preclinical Disease Models Variants Demonstrate Increased Efficacy Compared to Those Currently Available on the Market PARIS, France, Sept. 5, 2002 (PRIMEZONE) -- GenOdyssee S.A., a biotherapeutics company specializing in discovering and developing drugs from functional genomics, today announced preclinical results...